

# SAFETY DATA SHEET



## Levamisole (6.5%) / Oxclozanide (13%) Formulation

Version 5.0      Revision Date: 14.04.2025      SDS Number: 10857717-00009      Date of last issue: 28.09.2024  
Date of first issue: 29.09.2022

---

### SECTION 1. IDENTIFICATION

Product identifier : Levamisole (6.5%) / Oxclozanide (13%) Formulation

Other means of identification : COOPERS NILZAN LV ORAL DRENCH (36089)

#### Manufacturer or supplier's details

Company : MSD

Address : Rua Coronel Bento Soares, 530  
Cruzeiro - Sao Paulo - Brazil CEP 12730-340

Telephone : 908-740-4000

Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@msd.com

#### Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product

Restrictions on use : Not applicable

---

### SECTION 2. HAZARDS IDENTIFICATION

#### GHS Classification in accordance with ABNT NBR 14725 Standard

Acute toxicity (Oral) : Category 5

Serious eye damage : Category 1

Reproductive toxicity : Category 2

Specific target organ toxicity - single exposure (Oral) : Category 2 (Central nervous system)

Specific target organ toxicity - repeated exposure : Category 2 (Brain, Liver)

Short-term (acute) aquatic hazard : Category 2

Long-term (chronic) aquatic hazard : Category 2

#### GHS label elements in accordance with ABNT NBR 14725 Standard

# SAFETY DATA SHEET



## Levamisole (6.5%) / Oxclozanide (13%) Formulation

Version 5.0      Revision Date: 14.04.2025

SDS Number: 10857717-00009

Date of last issue: 28.09.2024  
Date of first issue: 29.09.2022

Hazard pictograms :



Signal Word : Danger

Hazard Statements : H303 May be harmful if swallowed.  
H318 Causes serious eye damage.  
H361d Suspected of damaging the unborn child.  
H371 May cause damage to organs (Central nervous system) if swallowed.  
H373 May cause damage to organs (Brain, Liver) through prolonged or repeated exposure.  
H411 Toxic to aquatic life with long lasting effects.

Precautionary Statements : **Prevention:**  
P201 Obtain special instructions before use.  
P264 Wash skin thoroughly after handling.  
P270 Do not eat, drink or smoke when using this product.  
P273 Avoid release to the environment.  
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

### Response:

P301 + P312 IF SWALLOWED: Call a POISON CENTER/ doctor if you feel unwell.  
P305 + P351 + P338 + P310 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Immediately call a POISON CENTER/ doctor.  
P308 + P311 IF exposed or concerned: Call a POISON CENTER/ doctor.  
P391 Collect spillage.

### Storage:

P405 Store locked up.

### Other hazards which do not result in classification

None known.

## SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

### Components

Chemical name	CAS-No.	Classification	Concentration (% w/w)
Oxclozanide	2277-92-1	Acute Tox. (Oral), 5 Repr., 2 STOT SE, (Oral)(Central nervous system), 2	>= 10 - < 20

## Levamisole (6.5%) / Oxclozanide (13%) Formulation

Version  
5.0

Revision Date:  
14.04.2025

SDS Number:  
10857717-00009

Date of last issue: 28.09.2024  
Date of first issue: 29.09.2022

		STOT RE, (Brain, Liver) , 2 Aquatic Acute, 1 Aquatic Chronic, 1	
Silicic acid, aluminum salt	1335-30-4	Eye Dam., 1	>= 5 -< 10
Levamisole hydrochloride	16595-80-5	Acute Tox. (Oral), 3 Repr., 2 STOT RE, (Oral)(Blood, Testis) , 2 Aquatic Acute, 3 Aquatic Chronic, 3	>= 5 -< 10
Citric acid	77-92-9	Eye Irrit., 2A STOT SE, 3	>= 1 -< 5

### SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.  
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.  
Remove contaminated clothing and shoes.  
Get medical attention.  
Wash clothing before reuse.  
Thoroughly clean shoes before reuse.

In case of eye contact : In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.  
If easy to do, remove contact lens, if worn.  
Get medical attention immediately.

If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention.  
Rinse mouth thoroughly with water.  
Never give anything by mouth to an unconscious person.

Most important symptoms and effects, both acute and delayed : May be harmful if swallowed.  
Causes serious eye damage.  
Suspected of damaging the unborn child.  
May cause damage to organs if swallowed.  
May cause damage to organs through prolonged or repeated exposure.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

### SECTION 5. FIRE-FIGHTING MEASURES

# SAFETY DATA SHEET



## Levamisole (6.5%) / Oxclozanide (13%) Formulation

Version 5.0	Revision Date: 14.04.2025	SDS Number: 10857717-00009	Date of last issue: 28.09.2024 Date of first issue: 29.09.2022
----------------	------------------------------	-------------------------------	---

Suitable extinguishing media	: Water spray Alcohol-resistant foam Carbon dioxide (CO2) Dry chemical
Unsuitable extinguishing media	: None known.
Specific hazards during fire fighting	: Exposure to combustion products may be a hazard to health.
Hazardous combustion products	: Carbon oxides Chlorine compounds Nitrogen oxides (NOx)
Specific extinguishing methods	: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for fire-fighters	: In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

## SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures	: Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
Environmental precautions	: Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g., by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
Methods and materials for containment and cleaning up	: Soak up with inert absorbent material. For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

**Levamisole (6.5%) / Oxclozanide (13%) Formulation**Version  
5.0Revision Date:  
14.04.2025SDS Number:  
10857717-00009Date of last issue: 28.09.2024  
Date of first issue: 29.09.2022

---

**SECTION 7. HANDLING AND STORAGE**

Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Do not breathe mist or vapors.  
Do not swallow.  
Do not get in eyes.  
Avoid prolonged or repeated contact with skin.  
Wash skin thoroughly after handling.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Keep container tightly closed.  
Do not eat, drink or smoke when using this product.  
Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.  
When using do not eat, drink or smoke.  
Wash contaminated clothing before re-use.  
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

Conditions for safe storage : Keep in properly labeled containers.  
Store locked up.  
Keep tightly closed.  
Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:  
Strong oxidizing agents  
Gases

---

**SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION****Ingredients with workplace control parameters**

Components	CAS-No.	Value type (Form of exposure)	Control parame- ters / Permissible concentration	Basis
Oxclozanide	2277-92-1	TWA	0.4 mg/m <sup>3</sup> (OEB 2)	Internal
Levamisole hydrochloride	16595-80-5	TWA	20 µg/m <sup>3</sup> (OEB 3)	Internal
		Further information: Skin Wipe limit	200 µg/100 cm <sup>2</sup>	Internal

**Engineering measures** : Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-

**Levamisole (6.5%) / Oxclozanide (13%) Formulation**

Version 5.0	Revision Date: 14.04.2025	SDS Number: 10857717-00009	Date of last issue: 28.09.2024 Date of first issue: 29.09.2022
----------------	------------------------------	-------------------------------	---

less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).

Minimize open handling.

**Personal protective equipment**

Respiratory protection	: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter type	: Particulates type
Hand protection	
Material	: Chemical-resistant gloves
Remarks	: Consider double gloving.
Eye protection	: Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Skin and body protection	: Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

**SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES**

Physical state	: suspension
Color	: yellow
Odor	: No data available
Odor Threshold	: No data available
pH	: No data available
Melting point/freezing point	: No data available
Initial boiling point and boiling range	: No data available
Flash point	: No data available
Evaporation rate	: No data available

# SAFETY DATA SHEET



## Levamisole (6.5%) / Oxyclozanide (13%) Formulation

Version 5.0	Revision Date: 14.04.2025	SDS Number: 10857717-00009	Date of last issue: 28.09.2024
			Date of first issue: 29.09.2022

---

Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	No data available
Relative vapor density	:	No data available
Relative density	:	No data available
Density	:	No data available
Solubility(ies)		
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle characteristics		
Particle size	:	Not applicable

---

## SECTION 10. STABILITY AND REACTIVITY

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	Can react with strong oxidizing agents.
Conditions to avoid	:	None known.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

---

## SECTION 11. TOXICOLOGICAL INFORMATION

**Levamisole (6.5%) / Oxylozanide (13%) Formulation**Version  
5.0Revision Date:  
14.04.2025SDS Number:  
10857717-00009Date of last issue: 28.09.2024  
Date of first issue: 29.09.2022

Information on likely routes of exposure : Inhalation  
Skin contact  
Ingestion  
Eye contact

**Acute toxicity**

May be harmful if swallowed.

**Product:**

Acute oral toxicity : Acute toxicity estimate: 2.513 mg/kg  
Method: Calculation method

**Components:****Oxylozanide:**

Acute oral toxicity : LD50 (Rat): 3.519 mg/kg  
Target Organs: Central nervous system

Acute toxicity (other routes of administration) : LDLo (sheep): 10 mg/kg  
Application Route: Intravenous

**Silicic acid, aluminum salt:**

Acute oral toxicity : LD50 (Rat, female): > 2.000 mg/kg  
Method: OECD Test Guideline 423  
Assessment: The substance or mixture has no acute oral toxicity

Acute dermal toxicity : LD50 (Rabbit): > 5.000 mg/kg  
Remarks: Based on data from similar materials

**Levamisole hydrochloride:**

Acute oral toxicity : LD50 (Rat): 180 mg/kg  
LD50 (Mouse): 223 mg/kg  
LD50 (Rabbit): 458 mg/kg

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

**Citric acid:**

Acute oral toxicity : LD50 (Mouse): 5.400 mg/kg

Acute dermal toxicity : LD50 (Rat): > 2.000 mg/kg  
Method: OECD Test Guideline 402  
Assessment: The substance or mixture has no acute dermal toxicity

**Skin corrosion/irritation**

Not classified based on available information.

**Levamisole (6.5%) / Oxclozanide (13%) Formulation**Version  
5.0Revision Date:  
14.04.2025SDS Number:  
10857717-00009Date of last issue: 28.09.2024  
Date of first issue: 29.09.2022**Components:****Oxclozanide:**

	Remarks	: Not classified due to lack of data.
--	---------	---------------------------------------

**Silicic acid, aluminum salt:**

	Species	: Rabbit
	Method	: OECD Test Guideline 404
	Result	: No skin irritation
	Remarks	: Based on data from similar materials

**Levamisole hydrochloride:**

	Remarks	: No data available
--	---------	---------------------

**Citric acid:**

	Species	: Rabbit
	Method	: OECD Test Guideline 404
	Result	: No skin irritation

**Serious eye damage/eye irritation**

Causes serious eye damage.

**Components:****Oxclozanide:**

	Remarks	: Not classified due to lack of data.
--	---------	---------------------------------------

**Silicic acid, aluminum salt:**

	Species	: Chicken eye
	Method	: Chorioallantoic membrane vascularization assay
	Result	: Irreversible effects on the eye

**Levamisole hydrochloride:**

	Remarks	: No data available
--	---------	---------------------

**Citric acid:**

	Species	: Rabbit
	Result	: Irritation to eyes, reversing within 21 days
	Method	: OECD Test Guideline 405

**Respiratory or skin sensitization****Skin sensitization**

Not classified based on available information.

**Respiratory sensitization**

Not classified based on available information.

**Levamisole (6.5%) / Oxyclozanide (13%) Formulation**Version  
5.0Revision Date:  
14.04.2025SDS Number:  
10857717-00009Date of last issue: 28.09.2024  
Date of first issue: 29.09.2022**Components:****Oxyclozanide:**

Routes of exposure	:	Dermal
Remarks	:	Not classified due to lack of data.

**Silicic acid, aluminum salt:**

Test Type	:	Local lymph node assay (LLNA)
Routes of exposure	:	Skin contact
Species	:	Mouse
Method	:	OECD Test Guideline 429
Result	:	negative

**Levamisole hydrochloride:**

Remarks	:	No data available
---------	---	-------------------

**Germ cell mutagenicity**

Not classified based on available information.

**Components:****Oxyclozanide:**

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Result: negative
		Test Type: Chromosomal aberration Test system: Human lymphocytes Result: positive
		Test Type: Mouse Lymphoma Result: positive
Genotoxicity in vivo	:	Test Type: Micronucleus test Species: Mouse Application Route: Oral Result: negative
		Test Type: unscheduled DNA synthesis assay Species: Rat Cell type: Liver cells Application Route: Oral Result: negative
Germ cell mutagenicity - Assessment	:	Weight of evidence does not support classification as a germ cell mutagen.

**Silicic acid, aluminum salt:**

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Result: negative
		Test Type: Chromosome aberration test in vitro

## Levamisole (6.5%) / Oxyclozanide (13%) Formulation

Version  
5.0

Revision Date:  
14.04.2025

SDS Number:  
10857717-00009

Date of last issue: 28.09.2024  
Date of first issue: 29.09.2022

Result: negative

Remarks: Based on data from similar materials

### Genotoxicity in vivo

: Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)  
Species: Rat  
Application Route: Ingestion  
Result: negative  
Remarks: Based on data from similar materials

### Levamisole hydrochloride:

#### Genotoxicity in vitro

: Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: Chromosome aberration test in vitro  
Result: negative

### Citric acid:

#### Genotoxicity in vitro

: Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: in vitro micronucleus test  
Result: positive

Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

#### Genotoxicity in vivo

: Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)  
Species: Rat  
Application Route: Ingestion  
Result: negative

### Carcinogenicity

Not classified based on available information.

### Components:

#### Oxyclozanide:

||| Remarks : Not classified due to lack of data.

#### Silicic acid, aluminum salt:

Species	: Rat
Application Route	: Ingestion
Exposure time	: 104 weeks
Result	: negative
Remarks	: Based on data from similar materials

#### Levamisole hydrochloride:

||| Species : Mouse

**Levamisole (6.5%) / Oxclozanide (13%) Formulation**

Version 5.0      Revision Date: 14.04.2025      SDS Number: 10857717-00009      Date of last issue: 28.09.2024  
Date of first issue: 29.09.2022

Application Route	:	Oral
Exposure time	:	2 Years
NOAEL	:	80 mg/kg body weight
Remarks	:	No significant adverse effects were reported
Species	:	Rat
Application Route	:	Oral
Exposure time	:	2 Years
NOAEL	:	40 mg/kg body weight
Remarks	:	No significant adverse effects were reported

**Reproductive toxicity**

Suspected of damaging the unborn child.

**Components:****Oxclozanide:**

Effects on fertility	:	Test Type: Two-generation reproduction toxicity study Species: Rat, male and female Application Route: Oral General Toxicity Parent: NOAEL: 25 - 35 mg/kg body weight Symptoms: Reduced body weight, No effects on embryofetal and postnatal development. Result: No effects on fertility.
	:	Test Type: Two-generation reproduction toxicity study Species: Rat Application Route: Oral General Toxicity Parent: LOAEL: 75 - 100 mg/kg body weight Symptoms: Reduced body weight, No effects on embryofetal and postnatal development. Result: No effects on fertility.
	:	Test Type: Two-generation reproduction toxicity study Species: Rat Application Route: Oral Early Embryonic Development: LOAEL: 75 - 100 mg/kg body weight Result: No fetotoxicity., No teratogenic effects.
	:	Test Type: One-generation reproduction toxicity study Species: Rat Application Route: Oral General Toxicity Parent: LOAEL: 80 - 160 mg/kg body weight Result: No fetotoxicity., No teratogenic effects., No effects on fertility.
Effects on fetal development	:	Test Type: Development Species: Rat Application Route: Oral Developmental Toxicity: NOAEL: 200 mg/kg body weight Result: No fetotoxicity., No teratogenic effects.

**Levamisole (6.5%) / Oxclozanide (13%) Formulation**Version  
5.0Revision Date:  
14.04.2025SDS Number:  
10857717-00009Date of last issue: 28.09.2024  
Date of first issue: 29.09.2022

Test Type: Development  
Species: Rat  
Application Route: Oral  
General Toxicity Maternal: LOAEL: 100 mg/kg body weight  
Result: No fetotoxicity., No teratogenic effects.

Test Type: Development  
Species: Rabbit  
Application Route: Oral  
Developmental Toxicity: NOAEL: 32 mg/kg body weight  
Result: Fetotoxicity., Skeletal malformations.

Reproductive toxicity - Assessment : Suspected of damaging the unborn child.

**Silicic acid, aluminum salt:**

Effects on fetal development : Test Type: Embryo-fetal development  
Species: Rat  
Application Route: Ingestion  
Result: negative  
Remarks: Based on data from similar materials

**Levamisole hydrochloride:**

Effects on fertility : Test Type: Three-generation reproduction toxicity study  
Species: Rat  
Application Route: Oral  
Result: No significant adverse effects were reported

Effects on fetal development : Test Type: Embryo-fetal development  
Species: Rat  
Application Route: Oral  
Developmental Toxicity: NOAEL: 20 mg/kg body weight  
Result: Fetotoxicity.

Test Type: Embryo-fetal development  
Species: Rabbit  
Application Route: Oral  
Developmental Toxicity: LOAEL: 40 mg/kg body weight  
Result: Fetotoxicity.

Reproductive toxicity - Assessment : Some evidence of adverse effects on development, based on animal experiments.

**Citric acid:**

Effects on fetal development : Test Type: One-generation reproduction toxicity study  
Species: Rat  
Application Route: Ingestion  
Result: negative

**STOT-single exposure**

May cause damage to organs (Central nervous system) if swallowed.

**Levamisole (6.5%) / Oxclozanide (13%) Formulation**Version  
5.0Revision Date:  
14.04.2025SDS Number:  
10857717-00009Date of last issue: 28.09.2024  
Date of first issue: 29.09.2022**Components:****Oxclozanide:**

Routes of exposure	:	Oral
Target Organs	:	Central nervous system
Assessment	:	May cause damage to organs.

**Citric acid:**

Assessment	:	May cause respiratory irritation.
------------	---	-----------------------------------

**STOT-repeated exposure**

May cause damage to organs (Brain, Liver) through prolonged or repeated exposure.

**Components:****Oxclozanide:**

Target Organs	:	Brain, Liver
Assessment	:	May cause damage to organs through prolonged or repeated exposure.

**Levamisole hydrochloride:**

Target Organs	:	Blood, Testis
Assessment	:	May cause damage to organs through prolonged or repeated exposure.

**Repeated dose toxicity****Components:****Oxclozanide:**

Species	:	Rat
NOAEL	:	9 mg/kg
LOAEL	:	44,5 mg/kg
Application Route	:	Oral
Exposure time	:	3 Months
Target Organs	:	Brain, Liver, spleen, Adrenal gland
Symptoms	:	Liver effects

Species	:	Dog
NOAEL	:	5 mg/kg
LOAEL	:	25 mg/kg
Application Route	:	Oral
Exposure time	:	3 Months
Target Organs	:	Brain, Liver
Symptoms	:	blood effects, alteration in liver enzymes

**Silicic acid, aluminum salt:**

Species	:	Rat
NOAEL	:	> 100 mg/kg
Application Route	:	Ingestion
Exposure time	:	104 Weeks

**Levamisole (6.5%) / Oxclozanide (13%) Formulation**Version  
5.0Revision Date:  
14.04.2025SDS Number:  
10857717-00009Date of last issue: 28.09.2024  
Date of first issue: 29.09.2022**Remarks** : Based on data from similar materials**Levamisole hydrochloride:**

Species	:	Rat
NOAEL	:	2,5 mg/kg
Application Route	:	Oral
Exposure time	:	18 Months
Target Organs	:	Testis

Species	:	Dog
LOAEL	:	20 mg/kg
Application Route	:	Oral
Exposure time	:	18 Months
Target Organs	:	Blood

Species	:	Dog
LOAEL	:	40 mg/kg
Application Route	:	Oral
Exposure time	:	3 Months

**Citric acid:**

Species	:	Rat
NOAEL	:	4.000 mg/kg
LOAEL	:	8.000 mg/kg
Application Route	:	Ingestion
Exposure time	:	10 Days

**Aspiration toxicity**

Not classified based on available information.

**Components:****Oxclozanide:****Not applicable****Experience with human exposure****Components:****Oxclozanide:**

Ingestion	:	Symptoms: May cause, Gastrointestinal disturbance, Central nervous system depression
-----------	---	--

**Levamisole hydrochloride:**

Ingestion	:	Symptoms: Nausea, Vomiting, Headache, Dizziness, hypotension
-----------	---	--

**Levamisole (6.5%) / Oxylozanide (13%) Formulation**Version  
5.0Revision Date:  
14.04.2025SDS Number:  
10857717-00009Date of last issue: 28.09.2024  
Date of first issue: 29.09.2022**SECTION 12. ECOLOGICAL INFORMATION****Ecotoxicity****Components:****Oxylozanide:**

Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): 0,69 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
M-Factor (Acute aquatic toxicity)	:	1
M-Factor (Chronic aquatic toxicity)	:	1

**Silicic acid, aluminum salt:****Ecotoxicology Assessment**

Chronic aquatic toxicity	:	No toxicity at the limit of solubility.
--------------------------	---	---

**Levamisole hydrochloride:**

Toxicity to fish	:	LC50 (Oryzias latipes (Japanese medaka)): 37,3 mg/l Exposure time: 96 h Method: OECD Test Guideline 203
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): 64 mg/l Exposure time: 48 h Method: OECD Test Guideline 202

**Citric acid:**

Toxicity to fish	:	LC50 (Pimephales promelas (fathead minnow)): > 100 mg/l Exposure time: 96 h
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): 1.535 mg/l Exposure time: 24 h

**Persistence and degradability****Components:****Oxylozanide:**

Stability in water	:	Hydrolysis: 50 %(156 d) Method: OECD Test Guideline 111
--------------------	---	--

**Citric acid:**

Biodegradability	:	Result: Readily biodegradable. Biodegradation: 97 % Exposure time: 28 d Method: OECD Test Guideline 301B
------------------	---	---

**Levamisole (6.5%) / Oxclozanide (13%) Formulation**Version  
5.0Revision Date:  
14.04.2025SDS Number:  
10857717-00009Date of last issue: 28.09.2024  
Date of first issue: 29.09.2022**Bioaccumulative potential****Components:****Oxclozanide:**

Partition coefficient: n-octanol/water : log Pow: 3,99  
pH: 7  
Method: OECD Test Guideline 107

**Citric acid:**

Partition coefficient: n-octanol/water : log Pow: -1,72

**Mobility in soil****Components:****Oxclozanide:**

Distribution among environmental compartments : log Koc: 4,83  
Method: OECD Test Guideline 106

**Other adverse effects**

No data available

**SECTION 13. DISPOSAL CONSIDERATIONS****Disposal methods**

Waste from residues : Do not dispose of waste into sewer.  
Dispose of in accordance with local regulations.  
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

**SECTION 14. TRANSPORT INFORMATION****International Regulations****UNRTDG**

UN number : UN 3082  
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.  
(oxclozanide)  
Class : 9  
Packing group : III  
Labels : 9  
Environmentally hazardous : yes

**IATA-DGR**

UN/ID No. : UN 3082  
Proper shipping name : Environmentally hazardous substance, liquid, n.o.s.  
(Oxclozanide)  
Class : 9  
Packing group : III

# SAFETY DATA SHEET



## Levamisole (6.5%) / Oxclozanide (13%) Formulation

Version 5.0      Revision Date: 14.04.2025      SDS Number: 10857717-00009      Date of last issue: 28.09.2024  
Date of first issue: 29.09.2022

---

Labels : Miscellaneous  
Packing instruction (cargo aircraft) : 964  
Packing instruction (passenger aircraft) : 964  
Environmentally hazardous : yes

### IMDG-Code

UN number : UN 3082  
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.  
(Oxclozanide)  
Class : 9  
Packing group : III  
Labels : 9  
EmS Code : F-A, S-F  
Marine pollutant : yes

### Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

### Domestic regulation

#### ANTT

UN number : UN 3082  
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.  
(oxclozanide)  
Class : 9  
Packing group : III  
Labels : 9  
Hazard Identification Number : 90

### Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

---

## SECTION 15. REGULATORY INFORMATION

### Safety, health and environmental regulations/legislation specific for the substance or mixture

National List of Carcinogenic Agents for Humans - (LINACH) : Not applicable

Brazil. List of chemicals controlled by the Federal Police : Not applicable

### The ingredients of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

# SAFETY DATA SHEET



## Levamisole (6.5%) / Oxclozanide (13%) Formulation

Version 5.0	Revision Date: 14.04.2025	SDS Number: 10857717-00009	Date of last issue: 28.09.2024 Date of first issue: 29.09.2022
----------------	------------------------------	-------------------------------	---

IECSC : not determined

### SECTION 16. OTHER INFORMATION

Revision Date : 14.04.2025  
Date format : dd.mm.yyyy

#### Further information

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

#### Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECL - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a

# SAFETY DATA SHEET



## Levamisole (6.5%) / Oxclozanide (13%) Formulation

---

Version 5.0	Revision Date: 14.04.2025	SDS Number: 10857717-00009	Date of last issue: 28.09.2024 Date of first issue: 29.09.2022
----------------	------------------------------	-------------------------------	---

---

guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

BR / Z8